Other functions - modulation of cigarette smoke-induced alterations of microrna expression and lung tumors in mice treated with aspirin and naproxen
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Fox Chase Cancer Center
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $598,689
Award facts
- Opportunity
-
- N01CN2500278 Solicitation number
- Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Feb 27, 2012
- Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Dec 15, 2011
- Contract value 100% obligated
- $598,689.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Philadelphia, PA 19111, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $598,689 |
About this award
This is a cost-no-fee delivery order awarded by the National Cancer Institute (NCI) to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The $598,689 contract is for the modulation of cigarette smoke-induced alterations of microRNA expression and lung tumors in mice treated with aspirin and naproxen. This work is being performed under the NCI's Preclinical Efficacy and Intermediate Endpoint Biomarkers multiple-award indefinite delivery contract, which encompasses preclinical services for cancer prevention and interception research. The Institute for Cancer Research has previously conducted other cancer research projects as a prime contractor and subcontractor for federal agencies. No set-aside designation was used for this contract award.
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on September 21, 2012.
How much is contract HHSN26100003 worth?
The government has obligated $598,689 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201200015I, an indefinite delivery contract, on Preclinical Efficacy and Intermediate Endpoint Biomarkers.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award